Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma
A practical resource for nurses
(Sprache: Englisch)
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis....
Jetzt vorbestellen
versandkostenfrei
Buch (Kartoniert)
20.25 €
10 DeutschlandCard Punkte
sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenlose Rücksendung
Produktdetails
Produktinformationen zu „Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma “
Klappentext zu „Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma “
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: -DLBCL: an overview -CAR T cells -CAR T-cell products -Delivering CAR T-cell therapy and managing patient expectations -CAR T-cell therapy-related toxicities
Bibliographische Angaben
- Autoren: Richard J. Buka , Deidre Moloney
- 2022, 94 Seiten, 12 farbige Abbildungen, Maße: 15 x 21 cm, Kartoniert (TB), Englisch
- Verlag: Karger
- ISBN-10: 3318070246
- ISBN-13: 9783318070248
- Erscheinungsdatum: 16.03.2022
Sprache:
Englisch
Kommentar zu "Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma"
0 Gebrauchte Artikel zu „Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma".
Kommentar verfassen